Final Step of the 10-Year Vision under ACT for the Vision
First written in FY2016. 7 of 9 entries say "Restated". Latest entry: FY2019.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Achieved".
- FY2019AchievedAnnual report
「Under the previous medium-term management plan, we achieved results including the launch of Hernicore in Japan, progress in the development of new drugs including SI-613, and growth in the LAL business. At the same time, responding urgently to changes in the business environment, including fundamental reform of Japan’s drug-pricing system, a factor behind worsening profitability in the pharmaceutical business, and intensifying competition in overseas markets, has become a critical challenge.」
The previous medium-term management plan for fiscal 2016 through fiscal 2018 has concluded and is being reviewed, with achievements such as the launch of Hernicore in Japan and remaining challenges explicitly identified. - FY2019-Q3RestatedAnnual report
「Beginning in April 2016, we launched a 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking a Further Leap Forward” as the final step. We aim to overcome the challenging business environment, achieve the 10-Year Vision, and prevail as a Global Category Pharma.」
The final-step plan covering the fiscal years ending March 2017 through March 2019, together with its achievement targets, continues to be disclosed. - FY2019-Q2RestatedAnnual report
「Beginning in April 2016, we launched a 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking a Further Leap Forward” as the final step. We aim to overcome the challenging business environment, achieve the 10-Year Vision, and prevail as a Global Category Pharma.」
The final-step plan remains in place for the fiscal years ending March 2017 through March 2019. - FY2018-Q3RestatedAnnual report
「Beginning in April 2016, we launched a 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking a Further Leap Forward” as the final step. We aim to overcome the challenging business environment, achieve the 10-Year Vision, and prevail as a Global Category Pharma.」
The final-step plan covering the fiscal years ending March 2017 through March 2019, together with its achievement targets, remains in place. - FY2018-Q1RestatedAnnual report
「Beginning in April 2016, we launched a 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking a Further Leap Forward” as the final step. We aim to overcome the challenging business environment, achieve the 10-Year Vision, and prevail as a Global Category Pharma.」
The final-step plan remains in place for the fiscal years ending March 2017 through March 2019. - FY2017RestatedAnnual report
「Beginning in April 2016, we launched a 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking a Further Leap Forward” as the final step. We aim to overcome the challenging business environment, achieve the 10-Year Vision, and prevail as a Global Category Pharma.」
The final-step plan remains in place for the fiscal years ending March 2017 through March 2019. - FY2017-Q3RestatedAnnual report
「Beginning in April 2016, we launched a new 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking the Next Leap” as the final step, and will overcome the challenging business environment to achieve the 10-Year Vision and survive as a Global Category Pharma.」
The 3-year plan covering the fiscal years ending March 2017 through March 2019, which constitutes the final step, remains in place. - FY2017-Q1RestatedAnnual report
「Beginning in April 2016, we launched a new 3-year medium-term management plan under the key concept “ACT for the Vision — Achieving the 10-Year Vision and Taking the Next Leap” as the final step.」
The final-step plan covering the fiscal years ending March 2017 through March 2019 remains in place. - FY2016First statedAnnual report
「Based on the achievements and challenges identified under the previous medium-term management plan, we formulated a new 3-year medium-term management plan beginning in April 2016 as the final step of the 10-Year Vision.」
The key concept is “ACT for the Vision — Achieving the 10-Year Vision and Taking the Next Leap.” Priority areas are U.S. sales, SI-6603, new markets for existing products, production and quality control, and the research and development organization.